WO2026125953 - A GLP-1 RECEPTOR AGONIST
National phase entry is expected:
Publication Number
WO/2026/125953
Publication Date
18.06.2026
International Application No.
PCT/IB2025/060276
International Filing Date
10.10.2025
Title **
[English]
A GLP-1 RECEPTOR AGONIST
[French]
AGONISTE DU RÉCEPTEUR GLP-1
Applicants **
MAHRAT, Reem
Inventors
MAHRAT, Reem
Priority Data
18/973,854
09.12.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
ILPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2016 | |
| EPO | Filing, Examination, Granting | 8677 | |
| Japan | Filing, Examination, Granting | 2061 | |
| South Korea | Filing, Examination, Granting | 1933 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
20,027
Contact Us
Abstract[English]
The present disclosure relates to a GLP-1 receptor agonists to treat non-alcoholic fatty liver disease (NAFLD) and its advanced form, non-alcoholic steatohepatitis (NASH). The present disclosure also relates to the pharmaceutical composition comprising GLP-1 receptor agonists alone or in combination with other therapeutic agents. Moreover, the present disclosure relates to the kit comprising the GLP-1 receptor agonists and delivery system.[French]
La présente divulgation concerne des agonistes du récepteur GLP-1 pour traiter la stéatose hépatique non alcoolique (NAFLD) et sa forme avancée, la stéatohépatite non alcoolique (NASH). La présente divulgation concerne également la composition pharmaceutique comprenant des agonistes du récepteur GLP-1 seuls ou en combinaison avec d'autres agents thérapeutiques. En outre, la présente divulgation concerne le kit comprenant les agonistes du récepteur GLP-1 et un système d'administration.